bluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by JPMorgan Chase & Co.

bluebird bio (NASDAQ:BLUE) was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued on Monday,Briefing.com Automated Import reports.

BLUE has been the subject of a number of other reports. Barclays upped their target price on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 31st. Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $60.00 to $10.00 in a research report on Friday, November 15th. Finally, StockNews.com began coverage on bluebird bio in a report on Friday, December 20th. They set a “sell” rating for the company. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $49.14.

bluebird bio Stock Performance

Shares of BLUE opened at $4.08 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The stock has a market capitalization of $39.66 million, a PE ratio of -0.11 and a beta of 0.68. bluebird bio has a 12-month low of $4.00 and a 12-month high of $38.40. The business’s fifty day moving average price is $7.81 and its 200 day moving average price is $9.47.

Hedge Funds Weigh In On bluebird bio

Several institutional investors have recently modified their holdings of the business. Regeneron Pharmaceuticals Inc. bought a new stake in shares of bluebird bio in the fourth quarter valued at approximately $175,000. State Street Corp raised its position in bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 43,382 shares during the period. SG Americas Securities LLC increased its stake in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 74,185 shares during the period. Captrust Financial Advisors increased its position in shares of bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 77,293 shares during the period. Finally, Verition Fund Management LLC bought a new position in bluebird bio during the 3rd quarter valued at approximately $42,000. 87.43% of the stock is owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.